IPO TABLE: Three companies go public, two set IPO terms, two more file and one leaves the queue
This article was originally published in Scrip
Three biotechnology firms launched initial public offerings during the week of 15 to 19 September and each company ended its first day of trading above the IPO value – even Foamix Pharmaceuticals, which had to cut its price target in half to get its offering into the market.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.